Treatment of cancer chemotherapy‐associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma

Cancer

Volumn 71, Issue 5, 1993, Pages 1882-1892

  Snyder, Harry W ^a   Mittelman, Abraham ^b   Oral, Arsinur ^c   Messerschmidt, Gerald L ^d   Henry, David H ^e   Korec, Stefan ^f   Bertram, Juergen H ^g   Guthrie, Troy H ^h   Ciavarella, David ⁱ   Wuest, David ⁱ   Perkins, William ^a   Balint, Joseph P ^a   Cochran, Sharon K ^a   Peugeot, Reneé L ^a   Jones, Frank R ^a  

^a IMRÉ Corporation   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d WILFORD HALL MEDICAL CENTER   (United States)

^e GRADUATE HOSPITAL   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g North Idaho Cancer Center   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ Hudson Valley Blood Services ^*  (United States)

Author keywords

chemotherapy associated thrombotic thrombocytopenic purpura hemolytic uremic syndrome; circulating immune complexes (CIC); C TTP HUS; extracorporeal therapy; hemolytic uremic syndrome (HUS); immunoadsorption; PROSORBA column; protein A; staphylococcal protein A; thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; PROTEIN A;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER CHEMOTHERAPY; CHILL; CLINICAL FEATURE; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; ENDOTHELIUM LESION; EXTRACORPOREAL CIRCULATION; FEMALE; FEVER; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOADSORPTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; ANTIGEN-ANTIBODY COMPLEX; ANTINEOPLASTIC AGENTS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMAN; IMMUNOGLOBULIN G; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGE; NEOPLASMS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGRESSION ANALYSIS; STAPHYLOCOCCAL PROTEIN A; SURVIVAL ANALYSIS;

EID: 0027464913     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E     Document Type: Article

References (48)

1. Thrombocytopenia due to enhanced platelet destruction
2. Immune complex analysis and plasmapheresis in cancer related thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) syndrome
3. Mitomycin‐associated renal failure: case report and review
4. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy
5. Cancer‐associated hemolytic‐uremic syndrome: analysis of 85 cases from a national registry
6. Mitomycin‐induced hemolytic‐uremic syndrome: successful treatment with corticosteroids and intense plasma exchange
7. Hemorrhagic disorders: abnormalities of platelet and vascular function
8. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents
9. Mitomycin‐induced hemolytic uremic syndrome: case presentation and review of the literature
10. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy‐treated patients with adenocarcinoma
11. Treatment of cancer‐associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion
12. Gastric carcinoma and thrombotic thrombocytopenic purpura: association with plasma immune complex concentrations
13. The pathophysiology of circulating immune complexes: their role in host—tumor interactions and removal by immunoadsorption therapy
14. Protein A immunoadsorption therapy in HIV‐related immune thrombocytopenia: a preliminary report
15. Reduction in platelet‐binding immunoglobulins and improvement in platelet counts in patients with HIV‐associated idiopathic thrombocytopenic purpura (ITP) following extracorporeal immunoadsorption of plasma over staphylococcal protein A‐silica
16. Modulation of immunity in patients with autoimmune disease and cancer treated by extracorporeal immunoadsorption with PROSORBA columns
17. Protein A immunoadsorption in the treatment of malignant disease
18. Mitomycin C: interstitial pneumonitis and haemolytic uraemic syndrome
19. Microangiopathic hemolytic anemia: a frequent complication of mitomycin therapy in cancer patients
20. Pulmonary angiomatoid vascular changes in mitomycin C‐associated hemolytic uremic syndrome
21. Plasmapheresis and antiplatelet agents in the treatment of hemolytic uremic syndrome secondary to mitomycin
22. Microangiopathic hemolytic anemia, noncardiac pulmonary edema, and renal failure after treatment of metastatic adenocarcinoma of the colon with 5‐ fluorouracil and, mitomycin‐C: report of a case
23. Haemolytic‐uraemic syndrome complicating long‐term mitomycin‐C and 5‐fluorouracil therapy for gastric carcinoma
24. Treatment of mitomycin‐associated microangiopathic hemolytic anemia with vincristine
25. Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5‐fluorouracil
26. Renal disease after mitomycin C therapy
27. Complete necrotization of hepatocellular carcinoma by chemotherapy and subsequent intravascular coagulation: a case report
28. Effect of cyclophosphamide on the mitomycin‐induced syndrome of thrombotic thrombocytopenic purpura
29. Hemolytic anemia, thrombocytopenia and renal failure in a patient apparently cured of anal carcinoma
30. Microangiopathic hemolytic anemia, renal failure and non‐cardiogenic pulmonary edema: a chemotherapy induced syndrome
31. Intravascular haemolysis and renal impairment after blood transfusion in two patients on long‐term 5‐fluorouracil and mitomycin‐C
32. Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma
33. Chronic glomerular microangiopathy and metastatic carcinoma
34. Fatal mitomycin‐C (MMC) syndrome heralded by pulmonary symptoms [abstract]
35. Haemolysis and renal impairment syndrome in patients on 5‐fluorouracil and mitomycin‐C
36. Mitomycin C‐induced pulmonary and renal toxicities
37. Hemolytic‐uremic syndrome associated with mitomycin therapy
38. Reversible microangiopathic hemolytic anemia after mitomycin C
39. Renal failure and hemolytic anemia associated with mitomycin C: a case report
40. Mitomycin‐induced hemolytic‐uremic syndrome
41. Renal toxicity on mitomycin‐C
42. Mitomycin‐induced haemolysis and renal failure
43. Hemolytic uremic syndrome in a patient on cis‐platinum, vinblastine and bleomycin
44. Recovery from mitomycin C‐induced hemolytic uremic syndrome: a case report
45. Cisplatin‐associated hemolytic uremic syndrome: successful treatment with a staphylococcal protein A column
46. Carcinoma‐associated hemolytic uremic syndrome: a complication of mitomycin‐C chemotherapy
47. The effect of autologous plasma immunoadsorption by staphylococcal protein A (SpA) columns (PROSORBA) on T cell subsets and natural killer (NK) cells in patients with advanced cancer [abstract]
48. Effects of extracorporeal immunoadsorption with Prosorba‐staphylococcal protein A (SpA) column on parameters of cellular immunity [abstract]